Market Research Logo

Congestive Heart Failure: Major World Markets, Volume I: Pharmaceutical Management

Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment.

Kalorama Information's Congestive Heart Failure, Major World Markets series looks at CHF treatment. Volume I of this series looks at Pharmaceutical Treatments in the following key categories which are used to treat this disease:

  • ACEIs/ARBs
  • Beta-Blockers
  • Diuretics
  • Inotropes
  • Vasodilators
  • Aldosterone Inhibitors
This Kalorama Information report includes current market, market forecasts, product discussion and pipeline analysis are included for each segement of this report. General trends in this important disease category are also included. Relevant companies in the industry are profiled. This report is the result of Dr. Kenneth Krul's exhaustive analysis and primary research with key executives in the industry.
  • Abbott Laboratories
  • Actelion Pharmaceuticals US
  • Aldagen
  • Alexion Pharmaceuticals
  • AstraZeneca LP
  • Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
  • Bristol-Myers Squibb
  • CardioVascular Biotherapeutics
  • CoGenesys, Inc.
  • Encysive Pharmaceuticals
  • GlaxoSmithKline (US)
  • Inotek Pharmaceuticals
  • Mylan Pharmaceuticals
  • Novartis Pharmaceutical Corp.
  • Pfizer, Inc.
  • Roche Pharmaceuticals
  • Sanofi-Aventis (US)
  • Scios, Inc.
  • Vasogen, Inc.
  • Zealand Pharma


  • Executive Summary
    • BACKGROUND
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF MARKET
      • Table Estimated Market Sizes for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017 (US$ Billions)
    • MARKET TRENDS
    • THE NATURE OF THE INDUSTRY
      • Table Examples of Companies Competitive in Congestive Heart Failure Therapeutics
    • THE NEW TECHNOLOGIES
  • Introduction
    • BACKGROUND
      • Table International Cardiovascular Disease (CVD) Statistics (Rate per 100,000 Population)
      • Table United States CHF Statistics: 2004
    • PATHOPHYSIOLOGY
      • Table CHF Data Sources
    • TYPES OF HEART FAILURE
      • Left Ventricular (LV) Failure
    • Right Ventricular (RV) Failure
      • Systolic Dysfunction
      • Theories of Congestive Heart Failure
      • Hemodynamic Response Theory
      • Conditions Leading to Congestive Heart Failure
      • Myocardial Infarction
        • Table Common Contributors to Congestive Heart Failure
      • Cardiomyopathy
    • DIAGNOSIS OF CONGESTIVE HEART FAILURE
    • CLASSIFICATION OF CONGESTIVE HEART FAILURE PATIENTS
      • Epidemiology
      • United States
        • Table Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003
        • Table Incidence and Prevalence of CHF in the United States: 2007 - 2017 (Thousands)
      • Europe
        • Table The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets: 2007
        • Table Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 - 2017 (Thousands)
        • Table Incidence and Prevalence of CHF in Japan: 2007 - 2017 (Thousands)
  • Treatment of Congestive Heart Failure
    • Table Therapeutic Strategies for Symptomatic Congestive Heart Failure
    • PHARMACOLOGICAL THERAPY
      • Overview
        • Table Pharmacological Response to the Pathophysiology of Cardiac Performance
    • STANDARD PHARMACOLOGICAL THERAPY
      • ACE Inhibitors and Related Drugs
        • Table Common ACE Inhibitors Recommended for the Treatment of CHF
        • Table Common Angiotensin II Receptor Antagonists Recommended for the Treatment of CHF
        • Table Common b-Receptor Antagonists Recommended for the Treatment of CHF
        • Table Common Diuretics Recommended for the Treatment of CHF
        • Table Common Inotropic Drugs Available for the Treatment of CHF
        • Table Common Vasodilators Available for the Treatment of CHF
        • Table Common Aldosterone Blocking Drugs Recommended for the Treatment of CHF
    • EMERGING DRUGS TO TREAT CONGESTIVE HEART FAILURE
      • Table New Drugs in Development for the Treatment of CHF
  • Congestive Heart Failure Patient Management
    • GUIDELINES FOR MANAGEMENT OF CHRONIC HEART FAILURE
      • Table ACC/AHA Staging of Congestive Heart Failure
      • Table 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure
    • STRATEGIES TO MAINTAIN QUALITY PATIENT CARE AND CON`TAIN COSTS
      • Patient Education Programs
      • Dedicated Multidisciplinary Congestive Heart Failure Clinics
  • The Market for CHF Pharmaceuticals
    • MARKET ANALYSIS
      • Table Estimated Market Potential for CHF Pharmaceuticals in the Major World Healthcare Markets: 2007 - 2017 ($Billions)
      • United States
        • Table Estimated Market Potential for CHF Pharmaceuticals in the United States: 2007 - 2017 ($Billions)
      • Europe
        • Table Estimated Market Potential for CHF Pharmaceuticals in the Major European Markets: 2007 - 2017 ($Billions)
        • Table Estimated Market Potential for CHF Pharmaceuticals in the Japanese Market: 2007 - 2017 ($Billions)
  • Company Profiles
    • ABBOTT LABORATORIES
    • ACTELION PHARMACEUTICALS US
    • ALDAGEN
    • ALEXION PHARMACEUTICALS
    • ASTRAZENECA LP
    • BAYER HEALTHCARE PHARMACEUTICALS (BAYER SCHERING PHARMA)
    • BRISTOL-MYERS SQUIBB
    • CARDIOVASCULAR BIOTHERAPEUTICS
    • COGENESYS, INC.
    • ENCYSIVE PHARMACEUTICALS
    • GLAXOSMITHKLINE (US)
    • INOTEK PHARMACEUTICALS
    • MYLAN PHARMACEUTICALS
    • NOVARTIS PHARMACEUTICAL CORP.
    • PFIZER, INC.
    • ROCHE PHARMACEUTICALS
    • SANOFI-AVENTIS (US)
    • SCIOS, INC.
    • VASOGEN, INC.
    • ZEALAND PHARMA
  • Conclusions and Strategic Implications
    • FIRST CONCLUSION
    • SECOND CONCLUSION
    • THIRD CONCLUSION
    • FOURTH CONCLUSION
    • FIFTH CONCLUSION
    • SIXTH CONCLUSION
    • SEVENTH CONCLUSION
    • EIGHTH CONCLUSION
  • Glossary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report